Principles of Clinical Pharmacology

Edited by

  • Arthur Atkinson, Jr., Northwestern University, Chicago, Illinois , U.S.A.
  • Darrell Abernethy, National Institute on Aging, Baltimore, Maryland, U.S.A.
  • Charles Daniels, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA
  • Robert Dedrick, National Institute of Health, Bethesda, Maryland, U.S.A.
  • Sanford Markey, National Institute of Mental Health, Bethesda, Maryland, U.S.A.

This revised second edition covers the pharmacologic principles underlying the individualization of patient therapy and contemporary drug development, focusing on the fundamentals that underlie the clinical use and contemporary development of pharmaceuticals. Authors drawn from academia, the pharmaceutical industry and government agencies cover the spectrum of material, including pharmacokinetic practice questions, covered by the basic science section of the certifying examination offered by the American Board of Clinical Pharmacology. This unique reference is recommended by the Board as a study text and includes modules on drug discovery and development to assist students as well as practicing pharmacologists.
View full description


Clinical pharmacologists, pharmacologists, clinicians, pharmaceutical industry and government regulatory agencies


Book information

  • Published: September 2006
  • ISBN: 978-0-12-369417-1


"Recent advances in pharmacogenetics, membrane transport, and biotechnology warrant a second edition of this excellent book...This will serve as an excellent text for an advanced course in principles of clinical pharmacology for graduate students, physicians, and PharmDs. Because of recent advances, the second edition is welcome." - Thomas L. Pazdernik, PhD, University of Kansas Medical Center, FOR DOODY'S (4 Stars)

Table of Contents

Tentative TOC:Chapter 1 Introduction PART 1: PHARMACOKINETICS:Chapter 2 Clinical pharmacokinetics Chapter 3 Compartmental analysis of drug distribution Chapter 4 Drug absorption and bioavailability Chapter 5 Effects of renal disease on pharmacokineticsChapter 6 Kinetics of hemodialysis and hemofiltrationChapter 7 Effects of liver disease on pharmacokineticsChapter 8 Noncompartmental vs. compartmental approaches to pharmacokinetic analysisChapter 9 Distributed models of drug kineticsChapter 10 Population pharmacokineticsPART 2: DRUG METABOLISM AND TRANSPORT:Chapter 11 Pathways of drug metabolismChapter 12 Biochemical mechanisms of drug toxicityChapter 13 Chemical assay of drugs and drug metabolitesChapter 14 Equilibrative and concentrative transportChapter 15 PharmacogeneticsChapter 16 Drug interactionsPART 3: ASSESSMENT OF DRUG EFFECTS:Chapter 17 Physiological and laboratory markers of drug effectChapter 18 Dose response and concentration response analysisChapter 19 Kinetics of pharmacologic effectChapter 20 Disease progression models PART 4: OPTIMIZING AND EVALUATING PATIENT THERAPY:Chapter 21 Sex differences in pharmacokinetics and pharmacodynamicsChapter 22 Drug therapy in pregnant and nursing womenChapter 23 Drug therapy in neonates and pediatric patientsChapter 24 Drug therapy in the elderlyChapter 25 Clinical analysis of adverse drug reactionsChapter 26 Quality assessment of drug therapyPART 5: DRUG DISCOVERY AND DEVELOPMENT:Chapter 27 Project managementChapter 28 Drug discoveryChapter 29 Pre-clinical developmentChapter 30 Animal scale upChapter 31 Phase I studiesChapter 32 PK and PD considerations in the development of biotechnology products and large moleculesChapter 33 Design of clinical development programsChapter 34 Good design practices for clinical trials Chapter 35 Role of the FDA in guiding drug developmentAppendix I Table of Laplace TransformsAppendix II Answers to Study Problems